Evidence map›Paper›PMID 34330895›Full record

Trial reportBlood cancer journal2021

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.

H Parry, G McIlroy, R Bruton, M Ali, C Stephens, S Damery, A Otter, T McSkeane, H Rolfe, S Faustini and 7 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 13 pooled it
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 13 syntheses or guidelines pooled it, 129 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.Annals of oncology : official journal of the European Society for Medical Oncology · 2022
    Pooled it
  10. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

H ParryInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
G McIlroyInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
R BrutonInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
M AliInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
C StephensInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
S DameryInstitute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK.
A OtterNational infection Service, Public Health England, Porton Down, Salisbury, SP4 OJG, UK.
T McSkeaneCancer Research UK Clinical Trials Unit, University of Birmingham, B15 2TT, Birmingham, UK.
H RolfeCancer Research UK Clinical Trials Unit, University of Birmingham, B15 2TT, Birmingham, UK.
S FaustiniInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
N WallInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
P HillmenSt. James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, UK.
G PrattQueen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, B15 2TH, UK.
S PaneeshaBirmingham Heartlands Hospital, University Hospitals Birmingham, Bordesley Green East, B9 5SS, Birmingham, UK.
J ZuoInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.ORCID 0000-0002-8341-465X
A RichterInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
P MossInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK. P.moss@bham.ac.uk.ORCID 0000-0002-6895-1967
University of Birmingham · GBCancer Research UK Clinical Trials Unit · GBQueen Elizabeth Hospital Birmingham · GBHeartlands Hospital · GBLeeds Teaching Hospitals NHS Trust · GBPublic Health England · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines offer the potential for protection against severe infection but relatively little is known regarding the profile of the antibody response following first or second vaccination. We studied spike-specific antibody responses following first and/or second Covid-19 vaccination in 299 patients with CLL compared with healthy donors. 286 patients underwent extended interval (10-12 week) vaccination. 154 patients received the BNT162b2 mRNA vaccine and 145 patients received ChAdOx1. Blood samples were taken either by venepuncture or as dried blood spots on filter paper. Spike-specific antibody responses were detectable in 34% of patients with CLL after one vaccine (n = 267) compared to 94% in healthy donors with antibody titres 104-fold lower in the patient group. Antibody responses increased to 75% after second vaccine (n = 55), compared to 100% in healthy donors, although titres remained lower. Multivariate analysis showed that current treatment with BTK inhibitors or IgA deficiency were independently associated with failure to generate an antibody response after the second vaccine. This work supports the need for optimisation of vaccination strategy in patients with CLL including the potential utility of booster vaccines.

Indexed as

Antibodies, ViralCOVID-19COVID-19 VaccinesImmunization, SecondaryLeukemia, Lymphocytic, Chronic, B-CellAdultAgedAged, 80 and overAntibody FormationBNT162 VaccineFemaleHumansMaleMiddle AgedAntibodies, ViralBNT162 VaccineCOVID-19 Vaccines

Identifiers

PMID34330895
PMCPMC8323747
OpenAlexW3165224470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.